Compound Detail
CHEMBL4297750
FARICIMAB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL4297750 |
| Name | FARICIMAB |
| Phase | Approved |
| Structure Type | SEQ |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
10
Known Names
9
Indications
2
Mechanisms
Drug Information
| Molecule Type | Antibody |
| First Approval | 2022 |
| Availability | Prescription |
| Chirality | Single Enantiomer |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Angiopoietin-2 inhibitor | INHIBITOR | Angiopoietin-2 | ✓ | ✓ |
| Vascular endothelial growth factor A inhibitor | INHIBITOR | Vascular endothelial growth factor A, long form | ✓ | ✓ |
Indications
Diabetes Complications Macular Edema Macular Edema Retinal Neovascularization Wet Macular Degeneration Macular Degeneration Macular Degeneration Choroidal Neovascularization Eye Diseases
ATC Classification
S01LA09
faricimab
Level 1: SENSORY ORGANS
Level 2: OPHTHALMOLOGICALS
Data from ChEMBL 36 via Core Engine